Literature DB >> 7687637

Neutralization and infection-enhancement epitopes of influenza A virus hemagglutinin.

M Tamura1, R G Webster, F A Ennis.   

Abstract

We studied 18 mAb specific for the H3 hemagglutinin (HA) to analyze the relationships between neutralizing and infection-enhancing epitopes on the influenza HA. The mAb could be separated into three groups based on their neutralization (N) and enhancement (E) activity in assays with the prototype virus; group I (N+E+), group II (N+E-) and group III (N +/- E+). A representative mAb from each group was analyzed for its effect on the infectivity of a group of escape mutants, selected with mAb to three sites on the H3 HA, and wild-type H3 viruses to define the relationship between neutralizing epitopes and infection-enhancing epitopes. A group I mAb (N+E+), which recognized site A on the HA, neutralized virus infection at high concentrations of antibody and enhanced virus infection at low concentrations. A group II mAb (N+E-), which recognized site B, had high neutralizing but no enhancing activity. The failure of this mAb to enhance virus uptake was a result of the inability of the Fc portion of virus-mAb complexes to bind to Fc receptor. The addition of anti-murine IgG as a second antibody to these virus-mAb complexes augmented virus uptake. A group III mAb (N +/- E+), which recognized site C, had enhancing but little neutralizing activity. This is the first definition of distinct epitopes that induce neutralizing and/or enhancing mAb.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687637

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics.

Authors:  Katie L Winarski; Juanjie Tang; Laura Klenow; Jeehyun Lee; Elizabeth M Coyle; Jody Manischewitz; Hannah L Turner; Kazuyo Takeda; Andrew B Ward; Hana Golding; Surender Khurana
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-11       Impact factor: 11.205

2.  Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.

Authors:  Mary Dawn T Co; Masanori Terajima; Stephen J Thomas; Richard G Jarman; Kamonthip Rungrojcharoenkit; Stefan Fernandez; In-Kyu Yoon; Darunee Buddhari; John Cruz; Francis A Ennis
Journal:  Viral Immunol       Date:  2014-08-20       Impact factor: 2.257

3.  Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses.

Authors:  M Tamura; R G Webster; F A Ennis
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

4.  Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels.

Authors:  Atsushi Yamanaka; Saori Kosugi; Eiji Konishi
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

Review 5.  Antibody-Dependent Enhancement: ″Evil″ Antibodies Favorable for Viral Infections.

Authors:  Xiaoke Yang; Xin Zhang; Xiaotian Zhao; Mengqi Yuan; Kehui Zhang; Jingwen Dai; Xiangyu Guan; Hua-Ji Qiu; Yongfeng Li
Journal:  Viruses       Date:  2022-08-08       Impact factor: 5.818

6.  A comprehensive map of the influenza A virus replication cycle.

Authors:  Yukiko Matsuoka; Hiromi Matsumae; Manami Katoh; Amie J Eisfeld; Gabriele Neumann; Takeshi Hase; Samik Ghosh; Jason E Shoemaker; Tiago J S Lopes; Tokiko Watanabe; Shinji Watanabe; Satoshi Fukuyama; Hiroaki Kitano; Yoshihiro Kawaoka
Journal:  BMC Syst Biol       Date:  2013-10-02

Review 7.  Fc receptors in antibody-dependent enhancement of viral infections.

Authors:  Adam Taylor; Suan-Sin Foo; Roberto Bruzzone; Luan Vu Dinh; Nicholas J C King; Suresh Mahalingam
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988

Review 8.  Manipulation of cell surface macromolecules by flaviviruses.

Authors:  Robert Anderson
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.